Ming H Yang

US Patent:

8345984, Jan 1, 2013

Filed:

Jun 11, 2010

Appl. No.:

12/814328

Inventors:

Shuiwang Ji - Tempe AZ, US
Wei Xu - Los Gatos CA, US
Ming Yang - San Jose CA, US
Kai Yu - Santa Clara CA, US

Assignee:

NEC Laboratories America, Inc. - Princeton NJ

International Classification:

G06K 9/00
G06K 9/62
G06K 9/64

US Classification:

382190, 382103, 382155, 382156, 382279

Abstract:

Systems and methods are disclosed to recognize human action from one or more video frames by performing 3D convolutions to capture motion information encoded in multiple adjacent frames and extracting features from spatial and temporal dimensions therefrom; generating multiple channels of information from the video frames, combining information from all channels to obtain a feature representation for a 3D CNN model; and applying the 3D CNN model to recognize human actions.

US Patent:

20200190525, Jun 18, 2020

Filed:

May 31, 2018

Appl. No.:

16/617971

Inventors:

- Scottsdale AZ, US
Ming Yang - Chandler AZ, US
Huafang Lai - Chandler AZ, US

International Classification:

C12N 15/74
C12P 19/12
C12N 9/10
A61K 39/39
C07K 14/195

Abstract:

The present invention relates to the fields of genetically modified strains, vaccine adjuvants, and generally molecular biology and immunology. Provided herein are modified strains that produce lipopolysaccharide (LPS) having reduced toxicity or detoxified lipopolysaccharide, and methods of obtaining such strains for plant-based production of biologics. Also provided herein are uses of reduced or detoxified LPS as adjuvants suitable for clinical use.

US Patent:

20180340181, Nov 29, 2018

Filed:

May 24, 2018

Appl. No.:

15/989060

Inventors:

- Scottsdale AZ, US
Haiyan Sun - Tempe AZ, US
Huafang Lai - Chandler AZ, US
Ming Yang - Chandler AZ, US

International Classification:

C12N 15/82
A61K 39/12
G01N 33/569
C12N 15/74

Abstract:

Compositions including a virus-like particle (VLP)-based vaccine displaying a portion of ZIKV envelope protein (E) domain III (DIII) and a portion of ZIKV envelope protein (E) and related methods are disclosed herein. Further, compositions including vaccines comprising a portion of ZIKA virus E protein, wherein the portion of ZIKA virus E protein is either a full-length version of ZIKA virus E protein or a functionally equivalent version of the full-length ZIKA virus E protein, are disclosed.